HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Spriel, A. B. Articles by van de Winkel, J. G. J. Search for Related Content PubMed PubMed Citation Articles by van Spriel, A. B. Articles by van de Winkel, J. G. J.

Neutrophil FcRI as Target for Immunotherapy of Invasive Candidiasis

Annemiek B. van Spriel^*,, Ingrid E. van den Herik-Oudijk^* and Jan G. J. van de Winkel^1,*,

^* Immunotherapy Laboratory, Medarex Europe, and Genmab, University Medical Center, Utrecht, The Netherlands

Invasive candidiasis represents a life-threatening disease for immunocompromised patients. This study focused on new immunotherapeutic approaches for systemic Candida albicans infections in a human FcRI-transgenic mouse model. FcRI (CD64) is a potent immunoactivating receptor on phagocytic and dendritic cells. In vivo targeting of C. albicans toward neutrophil-FcRI by bispecific Abs and G-CSF effectively protected FcRI-transgenic mice from lethal candidiasis. Nontransgenic mice were not protected, and treatment with bispecific Ab or G-CSF alone did not reduce mortality. Furthermore, infected FcRI-transgenic mice developed high titers of anti-C. albicans IgG, and survival was extended on secondary infection without further treatment. These findings document the capacity of FcRI to initiate potent anti-C. albicans immunity and support the development of FcRI-directed immunotherapy of invasive fungal disease.

This article has been cited by other articles:

				M. Ellis, B. al-Ramadi, U. Hedstrom, H. Alizadeh, V. Shammas, and J. Kristensen Invasive fungal infections are associated with severe depletion of circulating RANTES J. Med. Microbiol., November 1, 2005; 54(11): 1017 - 1022. [Abstract] [Full Text] [PDF]

				J. M. Beekman, J. E. Bakema, J. van der Linden, B. Tops, M. Hinten, M. van Vugt, J. G. J. van de Winkel, and J. H. W. Leusen Modulation of Fc{gamma}RI (CD64) Ligand Binding by Blocking Peptides of Periplakin J. Biol. Chem., August 6, 2004; 279(32): 33875 - 33881. [Abstract] [Full Text] [PDF]

				L. Bevaart, H. H. Van Ojik, A. W. Sun, T. H. Sulahian, J. H. W. Leusen, G. J. Weiner, J. G. J. van de Winkel, and M. J. Van Vugt CpG oligodeoxynucleotides enhance Fc{gamma}RI-mediated cross presentation by dendritic cells Int. Immunol., August 1, 2004; 16(8): 1091 - 1098. [Abstract] [Full Text] [PDF]

				P. J. Tacken, K. L. Hartshorn, M. R. White, C. van Kooten, J. G. J. van de Winkel, K. B. M. Reid, and J. J. Batenburg Effective Targeting of Pathogens to Neutrophils via Chimeric Surfactant Protein D/Anti-CD89 Protein J. Immunol., April 15, 2004; 172(8): 4934 - 4940. [Abstract] [Full Text] [PDF]

				H. H. van Ojik, L. Bevaart, C. E. Dahle, A. Bakker, M. J. H. Jansen, M. J. van Vugt, J. G. J. van de Winkel, and G. J. Weiner CpG-A and B Oligodeoxynucleotides Enhance the Efficacy of Antibody Therapy by Activating Different Effector Cell Populations Cancer Res., September 1, 2003; 63(17): 5595 - 5600. [Abstract] [Full Text] [PDF]

				M.-H. Rodier, C. Imbert, C. Kauffmann-Lacroix, G. Daniault, and J.-L. Jacquemin Immunoglobulins G could prevent adherence of Candida albicans to polystyrene and extracellular matrix components J. Med. Microbiol., May 1, 2003; 52(5): 373 - 377. [Abstract] [Full Text] [PDF]